Clinical trial
TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced…
NCT00089700 · Tanox, Industry · Unknown status
Key facts
| NCT number | NCT00089700 |
|---|---|
| Title | TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1 |
| Official title | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal Antibody TNX-355 With Optimized Background Therapy in Treatment-Experienced Subjects Infected With HIV-1 |
| Lead sponsor | Tanox, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | TNX-355 |
| Enrollment | 80 |
| Start date | Mar 1, 2004 |
| First posted | Aug 12, 2004 |
| Last update posted | Jun 24, 2005 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: